Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
info@chordiatherapeutics.com

This press release is an English translation of a Japanese-language press release. The
official language of this press release is Japanese, and the Japanese version takes
precedence over the English version in terms of content and interpretation.

<Press Release>
February 17, 2023
Chordia Therapeutics Inc, initiated Phase 1/ 2 Study of CTX-712, a CLK Inhibitor,
in Patients with Relapsed or Refractory acute myeloid leukemia or myelodysplastic
syndrome in the U.S.
Kanagawa, Japan, February 17, 2023 – Chordia Therapeutics Inc. (“Chordia”), abiotech company engaged in the research and development of novel therapies forcancers, today announced that Chordia has initiated a Phase 1/2 study of CTX-712, a
selective pan-CDC2-like kinase (“CLK”) inhibitor, in patients with relapsed orrefractory acute myeloid leukemia (“AML”) or myelodysplastic syndrome (“MDS”)
in the U.S.
This study is a multicenter, open label, Phase 1/2 study to evaluate safety and efficacyof CTX-712 in patients with relapsed or refractory AML or higher risk MDS. For more
information, please visit the following website at clinicaltrials.gov/ (NCT05732103).
About AML and MDS
AML and MDS are diseases in which abnormal stem cells (abnormal clones) growtumorigenically in the bone marrow and suppress normal hematopoiesis. The numberof patients with relapsed or refractory AML or MDS in US is estimated to beapproximately 14,000 and 11,000, respectively 1. Both diseases have not definitely
effective second-line therapies, have poor prognoses, and have a high unmet medicalneed.
About CTX-712
CTX-712 is a first-in-class, orally available and selective small molecule inhibitor of
CDC2-like kinase (CLK), a key regulator of the RNA splicing process that plays animportant role in cell growth. CTX-712 inhibits the growth of various human tumor
cell lines in vitro, and in addition, exhibits antitumor activity in multiple xenograft
mouse models in vivo.
Details of Phase 1 Clinical Trial in JapanThe Phase 1 clinical trial in Japan is investigating the tolerability, safety, andpharmacokinetics (PK) of CTX-712 in patients with advanced, relapsed, or refractory
malignancies. For details of the study, please refer to JapicCTI-184188.

Source: CancerMPact®, Cerner EnvizaSM / Synix Inc. (Diversion is strictly prohibitedsince such data is highly confidential)
1Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
info@chordiatherapeutics.com

Important Notice
In this press release, the definition of “press release” covers any oral presentation,question, and answer session, and written and/or oral materials discussed or distributedby Chordia Therapeutics in connection with this press release. This press release(including the oral description and related questions and answers) is not intended toconstitute, represent, or form part of any offer, invitation, or solicitation to purchase
and/or acquire anything, including securities.
Disclaimer
Any announcements by Chordia Therapeutics, including this press release, may
contain information on products derived from pharmaceutical developments, but areintended to inform the latest information related to Chordia’s business, and notintended as promotions, solicitations, advertisements, or to provide medical advice.
Forward-Looking Statements
This press release and materials distributed in connection with this press release may
contain forward-looking statements, information, beliefs, and opinions concerning our
future operations, future positioning, and performance, including estimates,
projections, goals, and plans. Forward-looking statements may include, but are notlimited to, expressions such as "goals," "plans," "beliefs," "hopes," "continues,""expects," "intends," "assures," "will," "may," "should," "would," "could," "estimates,""projects," and/or other similar expressions, or the negative thereof. These forwardlooking statements are based on assumptions concerning a number of important factors,
including the following, which could cause actual results to differ materially fromthose expressed or implied by the forward-looking statements; highly influential
factors that include economic conditions surrounding our global business, which
include general economic conditions in Japan and the United States, competitive
pressures and developments including changes in applicable laws and regulations,which include global healthcare reform, uncertainty as to our clinical success, andchallenges inherent in new product development (which include regulatory decisions
and their timing,) uncertainty as to the commercial success of new and existingproducts manufacturing difficulties, delays fluctuations in interest rates and exchange
rates claims or concerns regarding the safety or efficacy of commercial products or
product candidates the impact of a health crisis, such as the COVID-19 pandemic, on
Chordia and its customers and suppliers (including foreign governments in countries
in which the Company conducts business) or other aspects of its business. We
undertake no obligation to update any forward-looking statements contained in thispress release or any other forward-looking statements we may make, except as requiredby law or stock exchange rules. Past performance is not indicative of future operating
results, and any of our operating results or statements in this press release are notestimates, forecasts, warranties, or projections of our future operating results.

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
info@chordiatherapeutics.com

About Chordia Therapeutics
Chordia was established in November 2017 at Shonan Health Innovation Park(“Shonan iPark”) in Fujisawa, Kanagawa Prefecture, as a biotech company engaged
in the research and development of novel therapies for cancers, with the goal ofresearching and developing first-in-class anti-cancer drugs and creating innovative
new drugs.
In addition to its leading program for CTX-712, Chordia is engaged in the research ofseveral developments in our pipeline, including CTX-439, a CDK12 inhibitor, whichis expected to be effective in cancers with specific abnormalities, as well as GCN2inhibitors.
Established:
Address:
Representative:
Website:November 2017
26-1, Muraoka-Higashi 2-chome, Fujisawa,
Kanagawa 251-0012, Japan
Hiroshi Miyake, Representative Director
https://www.chordiatherapeutics.com/en/

For more information, contact IR Team: info@chordiatherapeutics.com